Cargando…
Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens ar...
Autores principales: | Semenas, Julius, Allegrucci, Cinzia, Boorjian, Stephen A, Mongan, Nigel P, Persson, Jenny Liao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474961/ https://www.ncbi.nlm.nih.gov/pubmed/22746994 http://dx.doi.org/10.2174/138945012802429615 |
Ejemplares similares
-
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013) -
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016) -
HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells
por: Shah, Mansi, et al.
Publicado: (2017) -
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
por: Bahmad, Hisham F., et al.
Publicado: (2022) -
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
por: Mandel, Anna, et al.
Publicado: (2018)